AU641267B2 - Solid preparation - Google Patents

Solid preparation Download PDF

Info

Publication number
AU641267B2
AU641267B2 AU82190/91A AU8219091A AU641267B2 AU 641267 B2 AU641267 B2 AU 641267B2 AU 82190/91 A AU82190/91 A AU 82190/91A AU 8219091 A AU8219091 A AU 8219091A AU 641267 B2 AU641267 B2 AU 641267B2
Authority
AU
Australia
Prior art keywords
solid preparation
document
organic solvent
preparation according
water
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU82190/91A
Other languages
English (en)
Other versions
AU8219091A (en
Inventor
Kozo Ishida
Yoshihiro Ishizue
Masanori Kubo
Toru Nishibayashi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Otsuka Pharmaceutical Co Ltd
Original Assignee
Otsuka Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Otsuka Pharmaceutical Co Ltd filed Critical Otsuka Pharmaceutical Co Ltd
Publication of AU8219091A publication Critical patent/AU8219091A/en
Application granted granted Critical
Publication of AU641267B2 publication Critical patent/AU641267B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU82190/91A 1990-07-19 1991-07-17 Solid preparation Ceased AU641267B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP19211290 1990-07-19
JP2-192112 1990-07-19

Publications (2)

Publication Number Publication Date
AU8219091A AU8219091A (en) 1992-02-18
AU641267B2 true AU641267B2 (en) 1993-09-16

Family

ID=16285866

Family Applications (1)

Application Number Title Priority Date Filing Date
AU82190/91A Ceased AU641267B2 (en) 1990-07-19 1991-07-17 Solid preparation

Country Status (9)

Country Link
US (1) US5316773A (enExample)
EP (1) EP0489181B1 (enExample)
JP (1) JPH07112975B2 (enExample)
KR (1) KR0172134B1 (enExample)
AU (1) AU641267B2 (enExample)
DE (1) DE69122478T2 (enExample)
DK (1) DK0489181T3 (enExample)
ES (1) ES2093106T3 (enExample)
WO (1) WO1992001453A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DZ3227A1 (fr) 1999-12-23 2001-07-05 Pfizer Prod Inc Compositions pharmaceutiques fournissant des concentrations de medicaments ameliorees
MXPA03011935A (es) * 2001-06-22 2004-03-26 Pfizer Prod Inc Composiciones farmaceuticas que contienen conjuntos de polimero y farmaco.
MY169670A (en) 2003-09-03 2019-05-08 Tibotec Pharm Ltd Combinations of a pyrimidine containing nnrti with rt inhibitors
DE10351644A1 (de) 2003-11-05 2005-06-09 Bayer Technology Services Gmbh Verfahren zur Herstellung von lagerstabilen multiplen Emulsionen
AR065720A1 (es) * 2007-03-14 2009-06-24 Tibotec Pharm Ltd Polvos para reconstitucion que comprenden rilpivirina dispersos en ciertos polimeros. uso. proceso.
EP3511417B1 (en) 2013-01-28 2023-05-31 Kansas State University Research Foundation Rift valley fever virus glycoproteins, gn and gc, and their use

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1018456A (en) * 1972-06-26 1977-10-04 Hans Lowey Prolonged release lozenges
US4127647A (en) * 1975-04-08 1978-11-28 Meiji Seika Kaisha, Ltd. Process for preparation of stable amorphous macrolide antibiotic solids
GB1579818A (en) * 1977-06-07 1980-11-26 Yamanouchi Pharma Co Ltd Nifedipine-containing solid preparation composition
CA1146866A (en) * 1979-07-05 1983-05-24 Yamanouchi Pharmaceutical Co. Ltd. Process for the production of sustained release pharmaceutical composition of solid medical material
JPS5899411A (ja) * 1981-12-05 1983-06-13 Shoichiro Ozaki 制ガン剤
JPS58109411A (ja) * 1981-12-23 1983-06-29 Shionogi & Co Ltd ニフエジピン固型製剤組成物
US4864021A (en) * 1984-10-30 1989-09-05 Otsuka Pharmaceutical Co., Ltd. 5-fluorouracil derivatives
GB8608080D0 (en) * 1986-04-02 1986-05-08 Fujisawa Pharmaceutical Co Solid dispersion composition
JPS63201127A (ja) * 1987-02-17 1988-08-19 Otsuka Pharmaceut Co Ltd ５−フルオロウラシル誘導体を含有する制癌剤
DK169520B1 (da) * 1986-07-25 1994-11-21 Otsuka Pharma Co Ltd 5-fluoruracilderivater, fremgangsmåde til deres fremstilling, anticancerpræparat indeholdende et sådant derivat og anvendelse af et sådant derivat til fremstilling af et præparat til behandling af cancer
JPS63115817A (ja) * 1986-11-04 1988-05-20 Mitsubishi Kasei Corp 肝疾患治療薬組成物
DE3877331T2 (de) * 1987-11-11 1993-05-27 Pharmascience Lab Exifon und ein wasserloesliches polymer enthaltende pharmazeutische zubereitung.
JPH0249720A (ja) * 1988-05-18 1990-02-20 Mitsubishi Kasei Corp 難溶性薬剤組成物
US5116600A (en) * 1989-01-05 1992-05-26 Otsuka Pharmaceutical Co., Ltd. Composition and method for inhibiting inflammation caused by non-parenteral administration of 5-fluorouracil type compounds
US5126145A (en) * 1989-04-13 1992-06-30 Upsher Smith Laboratories Inc Controlled release tablet containing water soluble medicament

Also Published As

Publication number Publication date
US5316773A (en) 1994-05-31
DK0489181T3 (da) 1996-11-18
JPH07112975B1 (enExample) 1995-12-06
AU8219091A (en) 1992-02-18
KR920702221A (ko) 1992-09-03
ES2093106T3 (es) 1996-12-16
EP0489181A4 (en) 1992-09-30
EP0489181B1 (en) 1996-10-02
DE69122478T2 (de) 1997-05-28
JPH07112975B2 (ja) 1995-12-06
EP0489181A1 (en) 1992-06-10
KR0172134B1 (ko) 1999-02-01
DE69122478D1 (de) 1996-11-07
WO1992001453A1 (fr) 1992-02-06

Similar Documents

Publication Publication Date Title
CA2752048C (en) Delayed release, oral dosage compositions that contain amorphous cddo-me
ZA200801362B (en) Solid pharmaceutical dosage form
CN102247601A (zh) 含有固体分散体与聚合物基质的药物组合物
AU688328B2 (en) Compositions in the form of solid solutions
EP1496864B1 (en) Pharmaceutical composition containing lamotrigine particles of defined morphology
US5316773A (en) Particulate preparation containing a flourracil derivative and hydroxypropylmethyl-cellulose
JPH1121241A (ja) 固形製剤組成物
CN108785260B (zh) 温敏性非甾体抗炎药固体分散体和速溶片及其制备方法
US20110152342A1 (en) Stabilized pharmaceutical composition
JP2001526227A (ja) バイオアベイラビリティーを高めた分子分散組成物
US20130331314A1 (en) Pharmaceutical composition for treating hcv infections
JPH04112824A (ja) ソファルコン含有固形製剤
Zhou et al. Bioavailability of ibuprofen from matrix pellets based on the combination of waxes and starch derivatives
CN101721351A (zh) 奈比洛尔或其药用盐固体分散体、其制备方法及其应用
US20060140991A1 (en) Pharmaceutical preparations having an improved solubility
JPWO1992001453A1 (ja) 固型製剤
CN106619532A (zh) 一种罗红霉素盐酸氨溴索干混悬剂及其制备方法
Thadanki et al. Fabrication and evaluation of Lercanidipine hydrochloride solid dispersions to improve its solubility and stability
EP4299063A1 (en) Oral capsules comprising atorvastatin tablets showing suitable dissolution profile and bioavailability
JPH0215026A (ja) 新規なプロブコール固形製剤
JPH0632737A (ja) 徐放性ニフェジピン製剤及びその製造方法
JP2813792B2 (ja) マレイン酸イルソグラジン経口投与用製剤およびその製造法
Dattatraya et al. Formulation and evaluation of fast dissolving tablets of Nizatidine
DATTATRAYA et al. Indian Journal of Novel Drug Delivery
US20070049634A1 (en) Microcrystals and pharmaceutical formulations comprising the same